Pipeline for SPAR primer design and analysis code is freely available at <https://github.com/felixhorns/spar>.

Introduction {#sec001}
============

Antibodies enable immune recognition by binding to target molecules called antigens. Characterization of antibody binding properties, such as specificity and affinity, is essential for understanding the recognition capability of the immune system and discovering antibodies for research and therapeutics. Currently, sequence information alone is not sufficient to predict antibody specificity and affinity. Thus, characterization of antibody binding requires recombinant cloning and expression of purified protein for use in functional assays.

Single-cell approaches enable high-throughput determination of native antibody sequences, but remain inadequate for functional characterization at similar scale. Droplet- and microwell-based single-cell sequencing techniques can identify \>10,000 natively paired antibody heavy- and light-chain gene sequences per experiment \[[@pone.0236477.ref001]--[@pone.0236477.ref004]\]. However, current methods yield complementary DNA (cDNA) pooled from thousands of cells, rendering isolation of antibody cDNA from individual cells difficult. Based on sequence information, antibody DNA can be produced by gene synthesis \[[@pone.0236477.ref003], [@pone.0236477.ref005]\], but this approach is more costly and time-consuming than cDNA cloning. Single B cell sorting and reverse transcription-polymerase chain reaction (RT-PCR) directly yields antibody cDNA suitable for cloning and expression \[[@pone.0236477.ref006]\], but this approach lacks sufficient throughput to survey antibody sequence diversity at the scale of the immune repertoire. Thus, existing methods do not permit simultaneous high-throughput determination of antibody sequences and the rapid cloning and expression of individual antibodies, which may be chosen from the repertoire on the basis of their sequence or clonal properties, for functional characterization.

In an effort to close this methodological gap, we envisioned a strategy for cloning antibody heavy- and light-chain cDNA from a single B cell within a pooled library by leveraging the unique sequence barcodes that are attached to molecules of cDNA during sample preparation. These sequence barcodes typically include a cell barcode (CBC) used to distinguish individual cells and a unique molecular identifier (UMI) used to distinguish individual molecules of template RNA ([Fig 1A](#pone.0236477.g001){ref-type="fig"}). After sequencing, the antibody heavy- and light-chain sequences, and their corresponding sequence barcodes are known. We reasoned that these barcodes and the heavy- and light-chain sequences could then be used as unique molecular tags to retrieve cDNA from a single cell.

![Schematic of workflow for Selective PCR for Antibody Retrieval (SPAR).\
(A) Antibody heavy- and light-chain cDNA (IGH and IGKL, respectively) from individual cells within a pooled library are distinguished by unique sequence barcodes (SB). For example, the heavy- and light-chain cDNA from cell 1 (IGH~1~ and IGKL~1~) are marked by SB~1~ and SB~1'~. (B) Molecule-specific primers are designed to target the sequence barcode. (C-E) Selective amplification of target molecules is performed by two-step nested PCR. Overview of nested PCR design for heavy (top) and light (bottom) chains in shown in (C) and details are shown in (D) and (E). In the first PCR step (PCR1), primers target the unique sequence barcode (SB) and constant region, labeled C. In the second PCR step (PCR2), primers target the 5' and 3' ends of the antibody variable region, labeled VDJ. (F) PCR products are cloned into linearized expression vectors by Gibson assembly. (G) Architecture of antibody heavy- or light-chain cDNA after library preparation using 10X Genomics Chromium 5' V(D)J platform. Sequence barcode consists of 16 bp cell barcode (CBC) and 10 bp unique molecular identifier (UMI). PCR1 forward primer targets this 26 bp sequence. PCR, polymerase chain reaction; cDNA, complementary DNA; IGH, immunoglobulin heavy chain; IGKL, immunoglobulin kappa or lambda chain; SB, sequence barcode; CBC, cell barcode; UMI, unique molecular identifier; V, variable gene; D, diversity gene; J, joining gene; C, constant gene.](pone.0236477.g001){#pone.0236477.g001}

Results {#sec002}
=======

Design of Selective PCR for Antibody Retrieval (SPAR) {#sec003}
-----------------------------------------------------

We designed a strategy for selective amplification of target cDNA molecules using PCR primers that specifically bind sequence barcodes ([Fig 1B](#pone.0236477.g001){ref-type="fig"}). Our strategy uses nested PCR consisting of two steps ([Fig 1C](#pone.0236477.g001){ref-type="fig"}). In the first step (PCR1), we use an outer forward primer that spans the sequence barcode, together with an outer reverse primer within the antibody constant region ([Fig 1D](#pone.0236477.g001){ref-type="fig"}). In the second step (PCR2), we use an inner forward primer targeting the 5' end of the variable region and an inner reverse primer targeting the 3' end of the variable region ([Fig 1E](#pone.0236477.g001){ref-type="fig"}). Importantly, the antibody repertoire has diversity throughout the variable region, with especially high diversity within complementarity determining region 3 (CDR3), which is located near the 3' end of the variable region, allowing PCR2 primers to enhance specificity. PCR2 yields full-length antibody variable region cDNA as a product. We designed the PCR2 primers with 5' arms that are homologous to the expression vector, enabling a simple one-step cloning procedure ([Fig 1F](#pone.0236477.g001){ref-type="fig"}).

We implemented this strategy for the 10X Genomics Chromium Single Cell 5' V(D)J platform. This platform uses a 16 base pair (bp) CBC and 10 bp UMI. After single-cell paired heavy- and light-chain sequencing, the complete heavy- and light-chain variable region sequences, and the corresponding CBC and UMI sequences for each cDNA molecule are known. Forward PCR1 primers were designed to target this combined 26 bp CBC and UMI sequence ([Fig 1G](#pone.0236477.g001){ref-type="fig"}). By performing computational primer design using Primer3 \[[@pone.0236477.ref007]\], we identified reverse PCR1 primers and PCR2 primer pairs that were compatible with these forward PCR1 primers and had high annealing temperature (optimally 67 C) to ensure specific amplification.

We tested this strategy using a dataset of sequences and material from our previous study \[[@pone.0236477.ref003]\]. This dataset consisted of 94,259 natively paired antibody heavy- and light-chain sequences obtained from single B cells, which were isolated from peripheral blood of healthy humans at 7 or 9 days after influenza vaccination. Single-cell paired heavy-light chain antibody repertoire sequencing was performed using the 10X Genomics Chromium Single Cell 5' V(D)J platform. Cells were pooled into 16 libraries, each having an average of 5,891 single cells (n = 5,891 ± 1,669, mean ± s.d., range 298--7,169 cells). For experimental validation, we used the full-length cDNA pools generated by the standard sample preparation procedure.

SPAR primers can be designed to retrieve most of the human antibody repertoire {#sec004}
------------------------------------------------------------------------------

To assess how much of the human antibody repertoire can be retrieved using SPAR, we computationally designed SPAR primers to retrieve antibodies from all 94,259 single cells in our dataset. Successful primer design is a necessary condition for antibody retrieval. Overall, we found that SPAR primers can be designed for 81% of these cells ([Fig 2A](#pone.0236477.g002){ref-type="fig"}). At the single-chain level, SPAR primers can be designed for 88% of heavy-chain genes and 90% of light-chain genes ([Fig 2A](#pone.0236477.g002){ref-type="fig"}). Because nearly all heavy- and light-chain genes were assembled based on sequencing of multiple molecules of cDNA, most antibodies can be addressed using multiple unique barcodes ([Fig 2B](#pone.0236477.g002){ref-type="fig"}; median 11 UMIs per heavy chain, 21 per light chain), improving the likelihood of having at least one suitable PCR1 primer pair. These results indicate that SPAR primers can be designed to retrieve the large majority of antibodies in the human repertoire.

![Computational design and characteristics of SPAR primers.\
(A) Success rates of SPAR primer design for heavy chain, light chain, and both chains for all cells in test dataset (n = 94,259 cells). (B) Number of cDNA molecules used to assemble each heavy- and light-chain contig (n = 94,259 heavy-chain contigs; n = 94,259 light-chain contigs). Each molecule carries a distinct unique molecular identifier (UMI). (C) Sequence similarity between PCR1 forward primers for all retrievable heavy-chain genes within one pooled library (n = 5,647 primers), as reflected in the distribution of edit distances to the nearest neighbor. Edit distance is defined as the number of insertions, deletions, or substitutions required to change one sequence to the other, also known as Levenshtein distance. (D) Predicted melting temperature of forward and reverse primers for all retrievable antibodies (n = 76,781). (E) Difference between predicted melting temperatures of forward and reverse primers in each pair for all retrievable antibodies (n = 76,781). Black dot indicates median. (F) Positions of forward and reverse primers for all retrievable antibodies (n = 76,781). Reverse primers are indicated by lighter shading, as in (D).](pone.0236477.g002){#pone.0236477.g002}

To assess the likely specificity of PCR1 primers targeting the sequence barcode, we examined the similarity between PCR1 forward primers for heavy-chain genes in one pooled library. We found that PCR1 forward primer sequences are substantially dissimilar ([Fig 2C](#pone.0236477.g002){ref-type="fig"}): the nearest sequence is 8 edits away on average, and the most similar pair of PCR1 forward primers is separated by 4 edits. These features suggest that PCR1 primers are sufficiently divergent to support selective amplification.

SPAR primers have favorable properties for PCR. Predicted melting temperatures of PCR1 primers are high ([Fig 2D](#pone.0236477.g002){ref-type="fig"}; 67.3 ± 1.1 C, mean ± s.d.) and well matched within pairs ([Fig 2E](#pone.0236477.g002){ref-type="fig"}; temperature difference 1.1 ± 1.3 C, mean ± s.d.). PCR2 primer pairs have greater variation in predicted melting temperature due to stronger constraints on primer position ([Fig 2D](#pone.0236477.g002){ref-type="fig"}; 59.4 ± 2.4 C, mean ± s.d.), but nevertheless have well matched melting temperature within pairs ([Fig 2E](#pone.0236477.g002){ref-type="fig"}; temperature difference 2.5 ± 2.6 C, mean ± s.d.). As designed, PCR2 primers flank the variable region ([Fig 2F](#pone.0236477.g002){ref-type="fig"}), permitting one-step cloning into expression vectors. Together, these features suggest that SPAR primers support efficient selective PCR.

SPAR retrieves full-length antibody variable region cDNA from single cells {#sec005}
--------------------------------------------------------------------------

To experimentally test retrieval of antibody cDNA, we performed SPAR on 8 target cells chosen at random from the cells with successful primer design within our dataset. We first performed SPAR PCR for these 8 cells. Agarose gel electrophoresis of the SPAR PCR2 products revealed successful retrieval of the expected, full-length antibody heavy- and light-chain variable region cDNA for all 8 targets (100%) ([Fig 3B and 3C](#pone.0236477.g003){ref-type="fig"}). We then cloned the cDNA for three of these antibodies into heavy- and light-chain expression vectors using Gibson assembly. Using Sanger sequencing, we confirmed that the target heavy- and light-chain sequences were retrieved for all three cells ([Fig 3D](#pone.0236477.g003){ref-type="fig"}). In every case, the retrieved heavy- and light-chain cDNA had perfect amino acid and DNA identity (100% identity) to the target ([Fig 3E](#pone.0236477.g003){ref-type="fig"}). These findings demonstrate that SPAR can retrieve full-length antibody cDNA from single cells within pooled libraries of \~5,000 cells with high fidelity and efficiency.

![Retrieval of antibodies from single cells using SPAR.\
(A) Molecular features of antibodies targeted for retrieval originating from 8 single cells chosen at random from pooled sequence libraries. Heavy- and light-chain gene usage and CDR3 length are shown. HV, heavy-chain variable; HJ, heavy-chain joining; HCDR3, heavy-chain CDR3; LV, light-chain variable; LJ, light-chain joining; LCDR3, light-chain CDR3; AA, amino acids. (B and C) Agarose gel electrophoresis of SPAR PCR2 products (2% agarose) for heavy- (B) and light-chain genes (C). Expected size of each product is indicated by label at bottom. (D) Sequence verification of SPAR PCR2 products using Sanger sequencing for three cells. Heavy- and light-chain amino acid sequences of SPAR PCR2 products were aligned to the reference sequences obtained by single-cell sequencing. Residues matching the reference are shown in green. (E) Summary of SPAR products for three cells. Colonies were picked after transformation of Gibson Assembly products into *E*. *coli*, then constructs were Sanger sequenced. For each chain, the fraction of colonies with perfect (100%) identity to reference is shown. One colony with maximal identity to reference was chosen, and the amino acid (AA) and DNA identity of that colony to the reference is shown.](pone.0236477.g003){#pone.0236477.g003}

Discussion {#sec006}
==========

SPAR enables a simple workflow for cloning antibody genes for functional characterization. After surveying antibody sequences at high-throughput using a single-cell sequencing approach, target antibodies can be chosen based on sequence or clonal characteristics, or single-cell phenotypes, such as transcriptome profile \[[@pone.0236477.ref003]\]. Using SPAR, these antibodies can be cloned and expressed directly from the pooled cDNA library. Our computational analysis suggests that \~81% of human antibodies can be retrieved by SPAR. Notably, many antibodies of practical interest belong to expanded clones, and antibodies that cannot be retrieved by SPAR due to primer constraints may nevertheless be clonally related to antibodies which have highly similar sequence and are retrievable. Furthermore, PCR-based mutagenesis could be used to generate variants in sequence space near retrieved antibodies. SPAR costs \~\$70 per antibody ([Table 1](#pone.0236477.t001){ref-type="table"}), which is cheaper than or similar in price to gene synthesis. Importantly, SPAR can be performed within \~29 hours ([Table 2](#pone.0236477.t002){ref-type="table"}), which is faster than the several-week turnaround time of gene synthesis. The speed of SPAR may be advantageous in scenarios requiring rapid response, such as antibody discovery for treatment of emerging infectious disease. Thus, SPAR enables rapid, low-cost cloning and expression of native antibodies from pooled sequencing libraries.

10.1371/journal.pone.0236477.t001

###### Cost analysis of Selective PCR for Antibody Retrieval (SPAR).

![](pone.0236477.t001){#pone.0236477.t001g}

  Reagent                       Supplier          Catalog No.   Cost (\$)
  ----------------------------- ----------------- ------------- -----------
  Oligo PCR1 Forward primer     IDT                             5.00
  Oligo PCR1 Reverse primer     IDT                             5.00
  Oligo PCR2 Forward primer     IDT                             10.00
  Oligo PCR2 Reverse primer     IDT                             10.00
  KAPA HiFi HotStart ReadyMix   KAPA Biosystems   KK2601        3.93
  ExoSAP-IT PCR Cleanup Mix     ThermoFisher      78200         0.85
  Ampure XP beads               Beckman Coulter   A63880        0.19
  **Total cost per chain**                                      34.97
  **Total cost per antibody**                                   69.94

10.1371/journal.pone.0236477.t002

###### Time requirements for Selective PCR for Antibody Retrieval (SPAR).

![](pone.0236477.t002){#pone.0236477.t002g}

  Step                Time (hours)   Hands-on time (hours)
  ------------------- -------------- -----------------------
  Design of primers   1              1
  Primer synthesis    24             
  SPAR PCR1           2              0.5
  SPAR PCR2           2              0.5
  **Total time**      29             2

Approximate times required to perform each step of the SPAR protocol are indicated. Primer synthesis time typically depends on turnaround time from oligonucleotide synthesis vendors.

SPAR could be improved and extended in several ways. To improve specificity, the primer design algorithm could explicitly model and penalize potential mispriming within the cDNA pool. To further improve specificity and efficiency, the single-cell sequencing library preparation procedure could be modified to incorporate a longer sequence barcode. Similar barcoding schemes are used in other single-cell sequencing approaches, such as Drop-seq \[[@pone.0236477.ref008]\], Microwell-seq \[[@pone.0236477.ref009]\], and SPLiT-seq \[[@pone.0236477.ref010]\], and these are also amenable to our approach. For \~10% of heavy- and light-chain genes, PCR primers satisfying standard constraints on predicted melting temperature, G/C content, and secondary structure could not be identified. While we have considered these genes irretrievable, fine-tuning of PCR conditions might allow them to be retrieved. Additionally, usage of longer sequence barcodes during library preparation would increase the likelihood that suitable SPAR PCR1 primers could be designed. Finally, although we successfully retrieved at least one clone with 100% AA and DNA sequence identity to the target in every case during validation ([Fig 3E](#pone.0236477.g003){ref-type="fig"}), we noted that other clones had suffered one or a few DNA base substitutions, as revealed by Sanger sequencing. We attribute these errors to the imperfect fidelity of the polymerases used for PCR steps, which could be mitigated by reducing the number of PCR cycles or using higher-fidelity polymerases.

SPAR builds upon previous tag-directed retrieval methods for gene synthesis \[[@pone.0236477.ref011], [@pone.0236477.ref012]\] and enrichment of transcriptomes \[[@pone.0236477.ref013]\]. The exceptional diversity of natural antibody sequences \[[@pone.0236477.ref014]\] plays a key role in enabling highly specific nested PCR, permitting retrieval of individual cDNA molecules within complex pools composed of \>10^7^ unique molecules. We anticipate that this approach will facilitate biophysical characterization of antibodies, accelerating antibody discovery and enhancing our understanding of the relationship between antibody sequence and function.

Materials and methods {#sec007}
=====================

Dataset {#sec008}
-------

For computational analysis and experimental validation, we used our previously published dataset consisting of 94,259 single B cells \[[@pone.0236477.ref003]\]. Briefly, the subject for this study was a female human aged 18 who was apparently healthy. Subject was vaccinated with the 2011--2012 seasonal trivalent inactivated influenza vaccine, and blood was collected by venipuncture 7 and 9 days afterwards (D7, D9), corresponding to the peak of the memory recall response \[[@pone.0236477.ref015]\]. Peripheral blood mononuclear cells (PBMCs) were isolated using a Ficoll gradient and frozen according to Stanford Human Immune Monitoring Center protocol.

After thawing, B cells were magnetically enriched using B Cell Isolation Kit II (Miltenyi), then single cells were encapsulated in droplets using 16 lanes of the Chromium device (10X Genomics) with target loading of 14,000 cells per lane. Reverse transcription and cDNA amplification were performed using the Direct Enrichment protocol of the Single Cell 5' V(D)J kit (10X Genomics). All steps were done according to manufacturer's instructions, except with additional cycles of PCR to obtain extra material for protocol testing (19 total cycles). Sequencing libraries were prepared using 50 ng of cDNA as input, then sequenced using the Illumina NextSeq 500 platform with paired-end reads of 150 bp each.

Antibody heavy- and light-chain transcripts were assembled for each cell using cellranger 2.1.0. Single B cells were identified by the presence of a single productive heavy chain and a single productive light chain, yielding a total of 94,259 single B cells.

Primer design for SPAR {#sec009}
----------------------

Primer design for SPAR consists of choosing nested PCR primers targeting the antibody gene of interest. In the 10X Genomics VDJ platform, each antibody sequence is typically assembled from sequencing reads from multiple cDNA molecules, which are tagged with the same cell barcode (CBC), but different unique molecular identifiers (UMIs). Accordingly, the gene can be addressed using a primer specific to the CBC and any of the UMIs. To design primers for PCR1, we first compiled a list of all UMIs supporting the antibody gene assembly, based on the output of cellranger 2.1.0. Full-length cDNA sequences were formed by concatenating partial read 1 primer, CBC, UMI, and template switch oligo (TSO) sequences to the assembled gene ([S1 Table](#pone.0236477.s001){ref-type="supplementary-material"}). Position of the constant region was determined based on the annotation provided by cellranger 2.1.0. Primers were generated using Primer3 4.1.0 with default parameters except PRIMER_OPT_SIZE = 26; PRIMER_MIN_SIZE = 22; PRIMER_MAX_SIZE = 35; PRIMER_OPT_TM = 67; PRIMER_MIN_TM = 53; PRIMER_MAX_TM = 72; PRIMER_MIN_GC = 30; PRIMER_MAX_GC = 70; PRIMER_SALT_DIVALENT = 2.5; PRIMER_DNA_CONC = 200; PRIMER_PRODUCT_SIZE_RANGE = 250--750. Target was specified as region bounded exclusively by the UMI and constant region, forcing primers to be selected within the CBC and UMI, and the constant region. Primers were allowed to include up to 5 bases of the partial read 1 sequence. Scores of primer pairs were aggregated across all UMIs and the best-scoring primer pair was accepted as the PCR1 primers.

We then designed primers for PCR2 that flank the antibody variable region. We determined the amplicon sequence produced by PCR1, then located the variable region sequence using IgBlast \[[@pone.0236477.ref016]\]. Primers were generated using Primer3 4.1.0 with default parameters except PRIMER_OPT_SIZE = 20; PRIMER_MIN_SIZE = 13; PRIMER_MAX_SIZE = 35; PRIMER_MIN_TM = 50; PRIMER_OPT_TM = 60; PRIMER_MAX_TM = 70; PRIMER_MIN_GC = 30; PRIMER_MAX_GC = 70; PRIMER_SALT_DIVALENT = 2.5; PRIMER_DNA_CONC = 200; PRIMER_PRODUCT_SIZE_RANGE = 100--700. The best-scoring primer pair was accepted as the PCR2 primers.

This workflow was implemented using custom Python scripts. For each individual cell, the workflow was carried out separately for the heavy- and light-chain genes.

Computational analysis of retrievability of human antibody repertoire {#sec010}
---------------------------------------------------------------------

To assess how much of the human antibody repertoire can be retrieved, we performed SPAR primer design for all single cells in our dataset (n = 94,259). We used the default parameters for SPAR primer design stated in the previous section. An antibody was defined as retrievable if acceptable primers were found for PCR1 and PCR2 for both heavy- and light-chain genes. To assess the sequence similarity between PCR1 forward primers, we calculated the edit distance, also known as the Levenshtein distance, between all pairs of acceptable PCR1 forward primers for one pooled library (chosen at random). Predicted melting temperatures were calculated using Primer3. Data visualization and analysis were performed using JupyterLab \[[@pone.0236477.ref017]\].

Experimental validation of SPAR {#sec011}
-------------------------------

To demonstrate that SPAR enables retrieval of single-cell antibody cDNA from pooled libraries, we chose 8 cells at random from our dataset. For each cell, SPAR primers designed using the above workflow were synthesized (IDT).

PCR1 was performed using 12.5 uL of HiFi ReadyMix 2X (Kapa Biosystems), 0.75 uL each of forward and reverse primer (final concentration 0.3 uM each), 1 uL of template, and 10 uL of water. Template was 0.5 ng of cDNA from single-cell sequencing library preparation. PCR1 protocol was 95 C for 3 min; 15 cycles of 98 C for 20 sec, 65 C for 15 sec, 72 C for 1 min; 72 C for 1 min. Primers from PCR1 were then degraded by adding 5 uL of PCR1 product to 2 uL of ExoSAP-IT (ThermoFisher), and incubating at 37 C for 15 min, then 80 C for 15 min.

PCR2 was performed using the same conditions, except using 1 uL of previous product as template. PCR2 protocol was 95 C for 3 min; 15 cycles of 98 C for 20 sec, 51 C for 15 sec, 72 C for 1 min; 72 C for 1 min. Products were visualized by electrophoresis using E-Gel EX 2% agarose gels (ThermoFisher).

To demonstrate one-step cloning of SPAR products into expression vectors and verify their sequences, we cloned the PCR2 products using Gibson assembly and performed Sanger sequencing. Heavy- and kappa-chain expression vectors were VRC01 CMV/R HC and VRC01 CMV/R LC \[[@pone.0236477.ref018]\], respectively. Lambda-chain expression vector was VRC01 CMV/R Lambda LC, which was created by replacing the kappa constant region with the lambda constant region in VRC01 CMV/R LC \[[@pone.0236477.ref018]\]. The reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CMVR VRC01 H/L, from Dr. John Mascola. Vectors were linearized by PCR. PCR conditions were the same as above, except 35 cycles were performed with annealing at 70 C, extension for 6 min, and final extension for 6 min. Template was 1 ng of vector. Products were purified using Ampure XP beads (Agencourt) at 0.7 bead to product volume ratio. Gibson assembly was performed using 10 uL of Gibson Assembly Master Mix (NEB), \~150 fmol insert, and \~50 fmol vector in a total volume of 20 uL. Products were transformed into E. cloni 10G Supreme cells (Lucigen) by electroporation following manufacturer's instruction. After overnight growth, eight colonies were picked and cultured in LB with 50 ug/mL kanamycin for 2 hours. Templates for colony PCR were prepared by diluting 10 uL of culture in 90 uL of water, then incubating at 95 C for 10 min. Colony PCR was performed using 12.5 uL of HiFi ReadyMix 2X (Kapa Biosystems), 0.75 uL each of forward and reverse sequencing primers (SeqF and SeqHR, SeqLR, or SeqKR; final concentration 0.3 uM each), 1 uL of template, and 10 uL of water. PCR protocol was 95 C for 3 min; 35 cycles of 98 C for 20 sec, 55 C for 15 sec, 72 C for 1 min; 72 C for 1 m. Sanger sequencing was performed on products using sequencing primers (Molecular Cloning Laboratories).

Supporting information {#sec012}
======================

###### Oligonucleotide sequences used in this study.

(XLSX)

###### 

Click here for additional data file.

###### 

(PDF)

###### 

Click here for additional data file.
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript by Horns and Quake presents an elegant method to retrieve monoclonal antibody sequences (VH and VL) from cDNA high-throughput sequencing data for subsequent production of recombinant antibodies. The method relies on the use of single-cell barcodes when performing single-cell sequencing to specifically amplify the antibody sequences of interest, by nested PCR. The authors first describe the computational methodology then moved onto a functional example from a 10x Genomics 5\' V(D)J sequencing experiment.

The manuscript is clearly written and will be helpful for a number of scientists performing single-cell antibody NGS using the 10X Genomics 5\' V(D)J kit and who would like to further characterise some antibodies sequenced.

Minor comments:

\(1\) Did the paired heavy-light chain sequencing cover the whole VH and VL sequences or just some CDRs? If only some CDRs are being sequenced, would this mean that some framework (FR) regions be missed? In particular the FR1, where the primers for PCR2 will bind.

\(2\) Why can SPAR primers be designed for only 88% of VH and 90% of VL? Can the barcodes misprime to other cDNA sequences? Or is it due to poor sequencing of the framework 1 or the VH or VL?

\(3\) Why was the retrieval and cloning of the VH and VL so inefficient in the end? Figure 3E shows that between 1 and 3 out of 8 clones had 100% DNA sequence identity

Reviewer \#2: Summary: The authors describe an approach to recover specific antibody amplicons from a pool of bulk cDNA for cloning and expression. Overall the manuscript is clearly written and easy to follow. The introduction, however, emphasizes that functional evaluation of antibodies is a bottleneck, which is true, but the proposed approach only addresses one piece of the functional screen bottleneck, which is cloning. It\'s a bit overstated to imply that the proposed approach addresses the functional screen bottleneck. Additionally, while I appreciate the arguments being made, I find tables 1 and 2 as not adding major contributions to the paper. Table 1 for example doesn\'t include personnel time. The cost of ordering the heavy and light chain genes for synthesis is \~\$100, so the cost argument isn\'t super strong given how easy it is to order genes these days. Second, Table 2 is a bit subjective - would 1 hr of hands on time for primer design be consistent for everyone? In many ways, it is much easier to just order the gene for synthesis. I think there\'s still value to the approach, however, for anyone who really wants to do an immediate PCR to recover HC+LC genes instead of waiting for gene synthesis, but I don\'t think this needs to be overhyped. I still think worth publishing in plos one.

Reviewer \#3: The authors report a very clever technique for rapidly extracting individual mAbs of interest from bulk 10x Genomics sequencing libraries. The manuscript is well written, the analyses and experiments are technically sound, and the data is clearly presented. I recommend acceptance and publication without any modification.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Bryan Briney

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to editor comments

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

We have revised the manuscript to conform to the style requirements.

2\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

All original gel images are now included as S1_raw_images. These images were used to generate Figure 3B and Figure 3C. We are providing this image data as Supplementary Information. We confirm that the gels reported in the main figures were prepared according to the guidelines. Specifically, no manipulation of the images was performed except for cropping empty lanes.

3\. We note that you have a patent relating to material pertinent to this article. Please provide an amended statement of Competing Interests to declare this patent (with details including name and number), along with any other relevant declarations relating to employment, consultancy, patents, products in development or modified products etc. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests> by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

We are preparing to submit a patent application related to this manuscript. We will provide an amended statement of Competing Interests as soon as the application is submitted and the patent name and number are available. This does not alter our adherence to PLOS ONE policies on sharing data and materials, and there are no restrictions on sharing of data or materials. We confirm that all authors do not have potential competing interests.

4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.

We are happy to add the ORCID iDs for all authors. However, when attempting to link the ORCID iD in Editorial Manager, we received a notice "The ORCID site reported the following error and the authorization process cannot be completed:" (The rest of the error message was blank). The ORCID iD of corresponding author Stephen Quake is <https://orcid.org/0000-0002-1613-0809>, and the ORCID iD of author Felix Horns is <https://orcid.org/0000-0001-5872-5061>.

Response to reviewers

Referee 1

\(1\) Did the paired heavy-light chain sequencing cover the whole VH and VL sequences or just some CDRs? If only some CDRs are being sequenced, would this mean that some framework (FR) regions be missed? In particular the FR1, where the primers for PCR2 will bind.

The paired heavy- and light-chain sequencing covers the entire VH and VL sequences. Thus, no framework regions are missed. We have added a sentence explaining this (Line 100).

\(2\) Why can SPAR primers be designed for only 88% of VH and 90% of VL? Can the barcodes misprime to other cDNA sequences? Or is it due to poor sequencing of the framework 1 or the VH or VL?

For \~10% of heavy- and light-chain genes, SPAR PCR primers satisfying constraints on predicted melting temperature, G/C content, and secondary structure could not be found. While we have considered these genes irretrievable, fine-tuning of PCR conditions might allow them to be retrieved. Additionally, if we used a library preparation method that incorporated a larger CBC and UMI, then there would be a higher likelihood that suitable SPAR PCR1 primers could be designed. We have added a comment on these sources of irretrievability and strategies to mitigate them in the Discussion (Line 183).

\(3\) Why was the retrieval and cloning of the VH and VL so inefficient in the end? Figure 3E shows that between 1 and 3 out of 8 clones had 100% DNA sequence identity

Nearly all of the clones without perfect DNA sequence identity to the target had suffered one or a few single base changes. We attribute this to the imperfect fidelity of the polymerases used for the various PCR steps. This issue could be mitigated by reducing the number of cycles of PCR or using higher fidelity polymerases. We have added a comment about this to the Discussion (Line 189).

Referee 2

The introduction, however, emphasizes that functional evaluation of antibodies is a bottleneck, which is true, but the proposed approach only addresses one piece of the functional screen bottleneck, which is cloning. It\'s a bit overstated to imply that the proposed approach addresses the functional screen bottleneck.

We agree that the functional evaluation of antibodies faces further bottlenecks downstream of cloning and expression. We have amended the main text in several places to emphasize that our method addresses the cloning bottleneck (Line 70 in the introduction and Line 162 in the discussion).

Additionally, while I appreciate the arguments being made, I find tables 1 and 2 as not adding major contributions to the paper. Table 1 for example doesn\'t include personnel time. The cost of ordering the heavy and light chain genes for synthesis is \~\$100, so the cost argument isn\'t super strong given how easy it is to order genes these days.

We have clarified that the cost of SPAR is cheaper than or similar in price to gene synthesis (Line 174).

Second, Table 2 is a bit subjective - would 1 hr of hands on time for primer design be consistent for everyone? In many ways, it is much easier to just order the gene for synthesis. I think there\'s still value to the approach, however, for anyone who really wants to do an immediate PCR to recover HC+LC genes instead of waiting for gene synthesis, but I don\'t think this needs to be overhyped.

We agree that the speed of SPAR is a valuable aspect. We have edited the text to emphasize that the turnaround time is faster than gene synthesis and to highlight the situations where this might be advantageous (Line 176). With respect to Table 2, while it is true that the times are subjective, we believe that it is helpful for practitioners of the method to understand the approximate timelines. This is often presented in molecular biology methods papers. We also believe that these timelines, while approximate, illustrate that the timescale is substantially faster than gene synthesis. Nevertheless, we have now indicated in the Table legend that these times are approximate.

###### 

Submitted filename: Rebuttal_200613.docx

###### 

Click here for additional data file.
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Cloning antibodies from single cells in pooled sequence libraries by selective PCR

PONE-D-20-13444R1

Dear Dr. Horns,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Kevin A. Henry

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I am pleased to say that the reviewers have found the revised manuscript suitable for publication in PLoS One. Congratulations on the very nice work. Reviewer 2 contacted me by email to confirm that their concerns had been addressed.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: All the comments have been properly addressed. The manuscript should be accepted as is, without any further improvements.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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Acceptance letter

Henry

Kevin A.

Academic Editor

© 2020 Kevin A. Henry

2020

Kevin A. Henry

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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PONE-D-20-13444R1

Cloning antibodies from single cells in pooled sequence libraries by selective PCR

Dear Dr. Horns:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kevin A. Henry

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**F.H. and S.R.Q. are inventors on a patent applied for by Stanford University and the Chan-Zuckerberg Biohub (CZB) (provisional patent application number 63/039,113) related to methods and compositions for selective PCR and cloning of antibody sequences. S.R.Q. is employed as co-president of CZB. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
